Videos 2016
 
  • 2/8/2016 Microneedle Arrays for Transdermal DeliveryManasi Chavan Ph.D,  BASF 

     Abstract: Intrinsic and Extrinsic skin aging causes several changes in the appearance of the skin, speci cally loss of elasticity and formation of skin aggregates. e presentation will focus on understanding the changes in the elastin com- ponent of the extracellular matrix of the skin as a result of aging. Manasi will be discussing the process of elastin biosynthesis and the role of LOXL in the elastin crosslinking and functionalization. Finally she will outline some of the strategies utilized to address the changes in age and UV associated  changes in skin elasticity. 
    Watch Video
 
  • 3/14/2016 Excipient Selection and the Effect on Performance and Physical Properties of Semi-solids: Amy Ethier Ph.D,  BASF 

     Abstract: One of the most established skin delivery systems, medicated semi-solids, continues to retain consumer attractiveness due to ease of application, absence of first pass metabolism, and localized drug delivery. Subtle differences in the physico-chemical framework associated with these systems may have a large effect on the performance and bioavailability of the drug agents. Specifically, these frameworks are composed of numerous possible microstructures including API polymorphs, surfactant phases, crystalline lipophiles, polymer networks and lipophile-surfactant gel or liquid crystalline phases. Thus, the selection of excipients in topical semi-solids will determine the structure of the microscopic phases during and after processing, and fundamentally alter the performance of the formulation; this is ultimately important for both formulators as well as the FDA. In this work, the complexity of PEG ointment formulations and o/w emulsions are investigated using various excipients. The influence of these ingredients on the physical properties of the formulations was observed by measuring viscosity and observing microstructure. Exemplary data will demonstrate how specific excipients were used to modify formulation performance, correct formulations that exhibited phase separation, and improve stability. 
    Watch Video
 
  • 4/18/2016 Efficacy of JAK Inhibitors in the Treatment of Alopecia Areata:Angela Christiano  Ph.D,  CUMC 

     Abstract: Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%. Current treatments including corticoste- roids and other immunomodulators are not FDA-approved and have demonstrated variable e cacy. In 2010, we published the  rst genome wide association study in AA, which revealed several susceptibility loci shared with other autoimmune diseases and in key pathways that regulate adaptive and innate immunity.  is evidence, in conjunction with gene expression pro ling, pointed to key members of the interferon-gamma (IFN γ) pathway, whose expression levels are markedly upregu- lated in AA. Since the IFNγ pathway is regulated in part by Janus kinases (JAKs), we recently conducted pre-clinical studies to ask whether immunosuppression with JAK inhibitors could induce hair regrowth in the C3H/HeJ gra  mouse model of AA. We found that both systemic as well as topical treatment with ruxolitinib (JAK1/2 inhibitor) or tofacitinib (JAK3 inhibi- tor) reversed established disease, a response that persisted for up to 3 months in 100% of mice treated. We next initiated an open label, proof-of-concept clinical trial for the treatment of moderate to severe AA in humans, using oral ruxolitinib 20mg BID. Twelve patients presented with severe, stable AA (greater than 50% hair loss) and were enrolled for 3-6 months of treat- ment. Nine out of 12 (75%) of patients demonstrated a remarkable response to the treatment, with up to 50% hair regrowth compared to baseline. By three months of therapy, responding patients had substantial hair regrowth compared to baseline, together with molecular evidence for normalization of biomarker signatures in scalp skin interrogated by gene expression pro ling. Similar clinical e cacy has also been observed in our ongoing open-label trial of tofacitinib in moderate to severe AA. Unexpectedly, recent work from our lab also found that JAK inhibition can also induce anagen hair growth in the mouse, and elongate the hair sha  in human organ culture assays, uncovering a new role for JAK inhibitors in modulating the normal hair cycle. Collectively, our results point to the potential bene t of JAK inhibitors in the treatment of alopecia areata, and potentially other forms of hair loss. 
    Watch Video
 
  • 11/7/2016 Biophysical Studies of Stratum Corneum Lipid Organization and Barrier Function - Changes Induced by pH, Surfactants and Temperature : Davide Moore Ph.D,  GSK 

     Abstract: Between 2003 to 2013 I, and several colleagues, undertook a series of biophysical studies at Unilever, ISP, TRI/ Princeton, and Rutgers University to investigate the impact on stratum corneum molecular organization of expo- sure to surfactant solutions of varying pH and chemistry. Subsequent studies also considered the impact of expo- sure time and temperature on barrier lipid dynamics. is presentation will discuss the biophysical experimental methods used in this work including FTIR spectroscopy, electron microscopy, and impedance while highlighting some of the key ndings from our published reports on these studies
    Watch Video
 
  • 11/29/2016 Introduction to Formulating for Efficacy Software : Mark Chandler Ph.D,  ACT Solutions Corp 

     Abstract: Mark Chandler is the President of a cosmetic and topical pharmaceutical industry consulting firm named ACT Solutions Corp. They have laborato- ries in Delaware and Ohio and currently focusing on Adaptive Aesthetic DesignTM, Advanced Emulsion SolutionsTM, and Formu- lating for EfficacyTM, including theFFETM Software developed by Dr. Johann Wiechers and Professor Steven Abbott, to speed develop- ment of products and ingredients with enhanced performance, aes- thetics, and consumer appeal. 
    Watch Video
 
  • 12/15/2016 Personal Care Product Development - Considerations on how to avoid pitfalls : Robert Falcone Ph.D, Nice Pak Industries 

     Abstract: We will discuss / share strategies on how new products should be developed on a domestic and global basis
    Watch Video